The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-04. Anything still debated is marked as such rather than presented as settled.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
A protease (also called a peptidase, proteinase, or proteolytic enzyme) is an enzyme that catalyzes proteolysis, breaking down proteins into smaller polypeptides or single amino acids, and spurring the formation of new protein products. They do this by cleaving the peptide bonds within proteins by hydrolysis, a reaction where water breaks bonds. Proteases are involved in numerous biological pathways, including digestion of ingested proteins, protein catabolism (breakdown of old proteins), and cell signaling. In the absence of functional accelerants, proteolysis would be very slow, taking hundreds of years. Proteases can be found in all forms of life including viruses. They have independently evolved multiple times, and different classes of protease can perform the same reaction by completely different catalytic mechanisms.
==== Internal ==== The phylogeny of the Asteroidea has been difficult to resolve, with visible (morphological) features proving inadequate, and the question of whether traditional taxa are clades apply. The phylogeny proposed by Gale in 1987 is:
== Reception and influence == A chapter in Hervé Le Tellier's novel Enough About Love pays homage to Edouard Levé, who appears as the character Hugues Léger, and to his book Autoportrait, the introspective and fragmentary style of which is imitated in an extract of a book titled Definition. Gérard Gavarry's book Expérience d'Edward Lee, Versailles (P.O.L., 2009) takes as its inspiration one hundred photos by Levé.
=== Periodicals === Links (magazine), a US golf magazine The Link (newspaper), a student newspaper at Concordia University, Canada The Link, the newsletter of the organization Americans for Middle East Understanding
Proto-oncogene tyrosine-protein kinase Fyn (p59-FYN, Slk, Syn, MGC45350, Gene ID 2534) is an enzyme that in humans is encoded by the FYN gene. Fyn is a 59-kDa member of the Src family of kinases typically associated with T-cell and neuronal signaling in development and normal cell physiology. Disruptions in these signaling pathways often have implications in the formation of a variety of cancers. By definition as a proto-oncogene, Fyn codes for proteins that help regulate cell growth. Changes in its DNA sequence transform it into an oncogene that leads to the formation of a different protein with implications for normal cell regulation. Fyn is a member of the protein-tyrosine kinase oncogene family. It encodes a membrane-associated tyrosine kinase that has been implicated in the control of cell growth. The protein associates with the p85 subunit of phosphatidylinositol 3-kinase and interacts with the fyn-binding protein. Alternatively spliced transcript variants encoding distinct isoforms exist.
Sources: en.wikipedia.org
Vice writer Patrick Klepek felt that the Headcrab was an iconic enemy known by people outside the Half-Life fandom, stating that due to it becoming more familiar, it became less intimidating, citing the fact that it was made into a plush. He felt that the Headcrabs in Half-Life: Alyx were responsible for making Headcrabs scary again, stating that it being a virtual reality game made its attacks that much more frightening. He felt that the Headcrabs being scary served as proof of how well Alyx works as a video game. Dread Central writer Justin Wood felt similarly about the virtual reality technology, stating that the sight of Headcrabs jumping at the player created "visceral reactions", as well as making him uncomfortable to hear them creeping around. Kotaku writer Nathan Grayson stated that, through his time playing Alyx, he had never gotten used to the "nauseating sense of dread" from the fear of being attacked by Headcrabs. He felt that this went beyond just being in virtual reality, praising the development team for managing to create such good sound design and animation that being accosted by Headcrabs inspired genuine fear in him. Twitch producer Mary Kish regarded Alyx as one of her favorite video games of 2020, stating that it being "genuinely scary" was a large part of why she liked it. She discussed how the Headcrabs function in it, which caused her to hold her breath in response to a Headcrab's presence, believing they pulled off a sense of danger well.
== History == Relugolix was first described in 2004. It superseded sufugolix (developmental code name TAK-013), which was developed by the same researchers. Relugolix was approved for the treatment of uterine fibroids in Japan in January 2019. It was the second orally active GnRH antagonist to be introduced for medical use, following elagolix (brand name Orilissa) in July 2018. Relugolix was approved for the treatment of prostate cancer in the United States on 18 December 2020. The FDA approved relugolix based on evidence from a clinical trial (NCT03085095) of 930 participants 48 to 97 years old with advanced prostate cancer. The trial was conducted at 155 sites in the United States, Canada, and countries in South America, Europe and the Asia Pacific region. All participants in the trial had advanced prostate cancer. Participants were randomly assigned to receive either one relugolix tablet daily (on the first day they received three tables) or an active control (leuprolide acetate) which was given as an injection under the skin every three months. The participants and healthcare providers were aware of which treatment was being given. The treatment lasted for 48 weeks. The efficacy of relugolix was assessed by the percentage of participants who achieved and maintained low testosterone level equal to castration.
== Mistaken portrait == For two centuries, until the discovery of the error in 2005, books, paintings and articles had incorrectly shown a profile portrait of the obscure French politician Louis Legendre (1752–1797) as a portrait of the mathematician. The error arose from the fact that the sketch was labelled simply "Legendre" and appeared in a book along with contemporary mathematicians such as Lagrange. One of only two known portraits of Legendre, rediscovered in 2008, is found in the 1820 book Album de 73 portraits-charge aquarellés des membres de I'Institut, a book of caricatures of seventy-three members of the Institut de France in Paris by the French artist Julien-Léopold Boilly as shown below. The other portrait is from the book Le Panthéon scientifique de la tour Eiffel.
=== Iodine === Iodine is used in chemistry as an indicator for starch. When starch is mixed with iodine in solution, an intensely dark blue colour develops, representing a starch/iodine complex. Starch is a substance common to most plant cells and so a weak iodine solution will stain starch present in the cells. Iodine is one component in the staining technique known as Gram staining, used in microbiology. Used as a mordant in Gram's staining, iodine enhances the entrance of the dye through the pores present in the cell wall/membrane. Lugol's solution or Lugol's iodine (IKI) is a brown solution that turns black in the presence of starches and can be used as a cell stain, making the cell nuclei more visible. Used with common vinegar (acetic acid), Lugol's solution is used to identify pre-cancerous and cancerous changes in cervical and vaginal tissues during "Pap smear" follow up examinations in preparation for biopsy. The acetic acid causes the abnormal cells to blanch white, while the normal tissues stain a mahogany brown from the iodine.
Sources: en.wikipedia.org
== Safety == PET scanning is non-invasive, but it does involve exposure to ionizing radiation. For a typical dose (245 MBq) of FDG, one of the most common radiotracers used for PET neuroimaging and cancer patient management, the effective radiation dose is 4.7 mSv. For combined PET–CT scanning, the radiation exposure contributed by the CT scan may be substantial - ranging from around 3–26 mSv (for a 70 kg person, and depending on the coverage and intended use of the scan). The amount of radiation in a typical FDG PET-CT scan is similar to the effective dose of spending one year in the American city of Denver, Colorado (12.4 mSv/year). For comparison, radiation dosage for other medical procedures range from 0.02 mSv for a chest X-ray and 6.5–8 mSv for a CT scan of the chest. Average civil aircrews are exposed to 3 mSv/year, and the IAEA recommend that whole body effective dose for nuclear energy workers is 20 mSv/year (when averaged over 5 years) and does not exceed 50 mSv in a given year.
=== Specialty training for interventional radiology === Training for interventional radiology occurs in the residency portion of medical education, and has gone through developments. In 2000, the Society of Interventional Radiology (SIR) created a program named "Clinical Pathway in IR", which modified the "Holman Pathway" that was already accepted by the American Board of Radiology to include training in IR; this was accepted by ABR but was not widely adopted. In 2005, SIR proposed, and ABR accepted another pathway called "DIRECT (Diagnostic and Interventional Radiology Enhanced Clinical Training) Pathway" to help trainees coming from other specialities learn IR; this too was not widely adopted. In 2006, SIR proposed a pathway resulting in certification in IR as a speciality; this was eventually accepted by the ABR in 2007 and was presented to the American Board of Medical Specialties (ABMS) in 2009, which rejected it because it did not include enough diagnostic radiology (DR) training. The proposal was reworked, at the same time that overall DR training was being revamped, and a new proposal that would lead to a dual DR/IR specialization was presented to the ABMS and was accepted in 2012 and eventually was implemented in 2014. By 2016 the field had determined that the old IR fellowships would be terminated by 2020. A handful of programs have offered interventional radiology fellowships that focus on training in the treatment of children.
== Interactions == Concomitant or recent (previous 14 days) monoamine oxidase inhibitor (MAOI) use can lead to hypertensive reactions, including hypertensive crisis, and should be avoided. Clinical studies have found minimal or no influence of certain MAOIs like the weak non-selective MAOI linezolid and the potent selective MAO-B inhibitor selegiline (as a transdermal patch) on the pharmacokinetics of pseudoephedrine. This is in accordance with the fact that pseudoephedrine is not metabolized by monoamine oxidase (MAO). However, pseudoephedrine induces the release of norepinephrine, which MAOIs inhibit the metabolism of, and as such, MAOIs can still potentiate the effects of pseudoephedrine. No significant pharmacodynamic interactions have been found with selegiline, but linezolid potentiated blood pressure increases with pseudoephedrine. However, this was deemed to be without clinical significance in the case of linezolid, though it was noted that some individuals may be more sensitive to the sympathomimetic effects of pseudoephedrine and related agents. Pseudoephedrine is contraindicated with MAOIs like phenelzine, tranylcypromine, isocarboxazid, and moclobemide due to the potential for synergistic sympathomimetic effects and hypertensive crisis. It is also considered to be contraindicated with linezolid and selegiline as some individuals may react more sensitively to coadministration.
Libraries of peptide aptamers have been used as "mutagens", in studies in which an investigator introduces a library that expresses different peptide aptamers into a cell population, selects for a desired phenotype, and identifies those aptamers that cause the phenotype. The investigator then uses those aptamers as baits, for example in yeast two-hybrid screens to identify the cellular proteins targeted by those aptamers. Such experiments identify particular proteins bound by the aptamers, and protein interactions that the aptamers disrupt, to cause the phenotype. In addition, peptide aptamers derivatized with appropriate functional moieties can cause specific post-translational modification of their target proteins, or change the subcellular localization of the targets.
=== Energy === Most civilian nuclear reactors, as well as all naval reactors, require fuel containing concentrated 235U, and production of that fuel generates depleted uranium as residue. Some power-generating reactors design are able to use unenriched fuel, for example the pressurized heavy-water reactors such as the CANDU design. However, as of 2013, about 10% of those built use that technology. Travelling wave reactors are a proposed type of reactor which can use depleted uranium as fuel.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.